The bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”
The current system of health technology development is characterised by multiple misalignments. The “supply” side (innovation policy-makers, entrepreneurs, investors) and the “demand” side (health policy-makers, regulators, health technology assessment, purchasers) operate under different – and conf...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
Kerman University of Medical Sciences
2017
|
| _version_ | 1797062129389404160 |
|---|---|
| author | Greenhalgh, T Fahy, N Shaw, S |
| author_facet | Greenhalgh, T Fahy, N Shaw, S |
| author_sort | Greenhalgh, T |
| collection | OXFORD |
| description | The current system of health technology development is characterised by multiple misalignments. The “supply” side (innovation policy-makers, entrepreneurs, investors) and the “demand” side (health policy-makers, regulators, health technology assessment, purchasers) operate under different – and conflicting – logics. The system is less a “pathway” than an unstable ecosystem of multiple interacting sub-systems. “Value” means different things to each of the numerous actors involved. Supply-side dynamics are built on fictions; regulatory checks and balances are designed to assure quality, safety and efficacy, not to ensure that technologies entering the market are either desirable or cost-effective. Assessment of comparative and cost-effectiveness usually comes too late in the process to shape an innovation’s development. <br/>We offer no simple solutions to these problems, but in the spirit of commencing a much-needed public debate, we suggest some tentative ways forward. First, universities and public research funders should play a more proactive role in shaping the system. Second, the role of industry in forging long-term strategic partnerships for public benefit should be acknowledged (though not uncritically). Third, models of “responsible innovation” and public input to research priority-setting should be explored. Finally, the evidence base on how best to govern inter-sectoral health research partnerships should be developed and applied. |
| first_indexed | 2024-03-06T20:41:09Z |
| format | Journal article |
| id | oxford-uuid:34544b86-2338-4f8e-81ec-14cbc26aed30 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:41:09Z |
| publishDate | 2017 |
| publisher | Kerman University of Medical Sciences |
| record_format | dspace |
| spelling | oxford-uuid:34544b86-2338-4f8e-81ec-14cbc26aed302022-03-26T13:25:15ZThe bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:34544b86-2338-4f8e-81ec-14cbc26aed30Symplectic Elements at OxfordKerman University of Medical Sciences2017Greenhalgh, TFahy, NShaw, SThe current system of health technology development is characterised by multiple misalignments. The “supply” side (innovation policy-makers, entrepreneurs, investors) and the “demand” side (health policy-makers, regulators, health technology assessment, purchasers) operate under different – and conflicting – logics. The system is less a “pathway” than an unstable ecosystem of multiple interacting sub-systems. “Value” means different things to each of the numerous actors involved. Supply-side dynamics are built on fictions; regulatory checks and balances are designed to assure quality, safety and efficacy, not to ensure that technologies entering the market are either desirable or cost-effective. Assessment of comparative and cost-effectiveness usually comes too late in the process to shape an innovation’s development. <br/>We offer no simple solutions to these problems, but in the spirit of commencing a much-needed public debate, we suggest some tentative ways forward. First, universities and public research funders should play a more proactive role in shaping the system. Second, the role of industry in forging long-term strategic partnerships for public benefit should be acknowledged (though not uncritically). Third, models of “responsible innovation” and public input to research priority-setting should be explored. Finally, the evidence base on how best to govern inter-sectoral health research partnerships should be developed and applied. |
| spellingShingle | Greenhalgh, T Fahy, N Shaw, S The bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title | The bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_full | The bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_fullStr | The bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_full_unstemmed | The bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_short | The bright elusive butterfly of value in health technology development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_sort | bright elusive butterfly of value in health technology development comment on providing value to new health technology the early contribution of entrepreneurs investors and regulatory agencies |
| work_keys_str_mv | AT greenhalght thebrightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT fahyn thebrightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT shaws thebrightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT greenhalght brightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT fahyn brightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT shaws brightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies |